Giammaria Giuliani
Angel Investor
Montagnola, Switzerland
Giammaria Giuliani is a Series B investor in Montagnola focused on Beauty and Biopharma. Giammaria Giuliani
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Giammaria Giuliani invests in
Stages Giammaria Giuliani invests in
Countries Giammaria Giuliani invests in
Round sizes
Round size
- Series B
- $22M–$43M
- Series C
- $28M–$39M
Investment Focus
Industry
- Beauty 1 (20%)
- Biopharma 1 (20%)
- Cosmetics 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series C 1 (20%)
Country
- Switzerland 1 (20%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cutiss
|
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $38.8M / Series C / Sep 10, 2025 | |
|
Cutiss
|
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $27.5M / Series C / May 17, 2024 | |
Bionaut Labs
|
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. | $43.2M / Series B / Nov 28, 2022 | |
|
Cutiss
|
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $19.6M / Series B / Jun 04, 2020 | |
|
Cutiss
|
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $8.5M / Series A / Jun 26, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Giammaria Giuliani invest in?
Giammaria Giuliani invests primarily in Beauty, Biopharma and Cosmetics startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Giammaria Giuliani's check size?
Giammaria Giuliani typically joins rounds of $22M–$43M at Series B and $28M–$39M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Giammaria Giuliani participates in.
When did Giammaria Giuliani last invest?
The most recent investment recorded for Giammaria Giuliani closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
